InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,002.00
(
2.66%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.39
(
-0.12%
)
Bitcoin
58,141.60
(
1.04%
)
Post# of 252897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: None

Wednesday, 04/16/2008 5:33:55 PM

Wednesday, April 16, 2008 5:33:55 PM

Post# of 252897
TEVA/(MNTA): Early Treatment with COPAXONE significantly delayed progression to clinically definite multiple sclerosis (46.55 +0.54) -Update-

http://biz.yahoo.com/bw/080416/20080416006361.html?.v=1

The co announces new results from the PreCISe study, which demonstrated that early treatment with COPAXONE significantly reduced the risk of developing clinically definite multiple sclerosis by 45% compared to placebo (hazard ratio 0.55, p=0.0001). These data were presented as late-breaking science at the 60th Annual Meeting of the American Academy of Neurology in Chicago. Based on the PreCISE results, an application for marketing authorization in Europe to the Medicines and Healthcare products Regulatory Agency for the extension of its indication to include the treatment of patients with a first clinical event suggestive of MS, was submitted and is currently under review. A similar application requesting an expanded label for COPAXONE(R) will also be submitted shortly with the FDA.



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up